Education
About Us
Working with TipRanks
Follow Us
Wuxi Biologics (Cayman) Inc. (HK:2269)
:2269
2269 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$10.14 - HK$29.30
Previous CloseN/A
Volume35.71M
Average Volume (3M)43.61M
Market Cap
$104.36B
Enterprise ValueHK$218.55B
Total Cash (Recent Filing)$10.71B
Total Debt (Recent Filing)¥4.94B
Price to Earnings (P/E)29.1
Beta1.72
Next Earnings
Aug 25, 2025EPS Estimate
0.49Last Dividend Ex-Date
Nov 02, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)0.25
Shares Outstanding4,068,680,700
10 Day Avg. Volume34,614,181
30 Day Avg. Volume43,606,167
Financial Highlights & Ratios
PEG Ratio1.62
Price to Book (P/B)6.29
Price to Sales (P/S)0.00
P/FCF Ratio-674.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$25.67Price Target Upside-0.52% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Wuxi Biologics (Cayman) News
PremiumCompany Announcements
WuXi Biologics Announces Share Placement by Substantial Shareholder
PremiumCompany Announcements
WuXi Biologics Announces AGM Results and Board Changes
PremiumCompany Announcements
WuXi Biologics Announces Board Composition and RolesPremiumCompany Announcements
Wuxi Biologics Grants Restricted Shares to Motivate EmployeePremiumCompany Announcements
Wuxi Biologics Announces 2025 Annual General Meeting Agenda
PremiumCompany Announcements
Wuxi Biologics Grants Over 25 Million Restricted Shares to EmployeesBulls Say, Bears Say
Bulls Say
Customer Demand And BacklogThere is a sustained robust customer demand, with the company's backlog growing to US$18.5bn, and a record increase in new projects, reinforcing its competitive position.
Market Share And Global ExpansionWuXi Biologics is a leading biologics R&D and manufacturing service provider with a 13% global market share, and is expanding its services overseas.
Revenue And Profit GrowthWuXi Biologics reported impressive results with a 9.6% increase in revenue and a 9.0% rise in adjusted net profit, indicating strong company performance.
Bears Say
Market SentimentThe bill has triggered negative market sentiment on Chinese CXOs, with the share prices of all Chinese CXOs correcting even for those companies without cell and gene therapy exposure.
Operational Risks In The USThe Biosecure Act could ban US companies from dealing with WuXi Biologics, affecting more than 50% of the company's business.
Regulatory RisksThe proposed US Biosecure Act poses regulatory headwinds, potentially affecting WuXi Biologics' business operations.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
6.14%
Mutual Funds
0.02% Other Institutional Investors
86.70% Public Companies and
Individual Investors
2269 FAQ
What was Wuxi Biologics (Cayman) Inc.’s price range in the past 12 months?
Wuxi Biologics (Cayman) Inc. lowest stock price was HK$10.14 and its highest was HK$29.30 in the past 12 months.
What is Wuxi Biologics (Cayman) Inc.’s market cap?
Wuxi Biologics (Cayman) Inc.’s market cap is $104.36B.
When is Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date?
Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date is Aug 25, 2025 which is in 51 days.
How were Wuxi Biologics (Cayman) Inc.’s earnings last quarter?
Wuxi Biologics (Cayman) Inc. released its earnings results on Mar 25, 2025. The company reported HK$0.246 earnings per share for the quarter, missing the consensus estimate of HK$0.482 by -HK$0.236.
Is Wuxi Biologics (Cayman) Inc. overvalued?
According to Wall Street analysts Wuxi Biologics (Cayman) Inc.’s price is currently Overvalued.
Does Wuxi Biologics (Cayman) Inc. pay dividends?
Wuxi Biologics (Cayman) Inc. pays a Notavailable dividend of HK$0.055 which represents an annual dividend yield of N/A. See more information on Wuxi Biologics (Cayman) Inc. dividends here
What is Wuxi Biologics (Cayman) Inc.’s EPS estimate?
Wuxi Biologics (Cayman) Inc.’s EPS estimate is 0.49.
How many shares outstanding does Wuxi Biologics (Cayman) Inc. have?
Wuxi Biologics (Cayman) Inc. has 4,068,680,700 shares outstanding.
What happened to Wuxi Biologics (Cayman) Inc.’s price movement after its last earnings report?
Wuxi Biologics (Cayman) Inc. reported an EPS of HK$0.246 in its last earnings report, missing expectations of HK$0.482. Following the earnings report the stock price went down -1.708%.
Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) Inc.?
Currently, no hedge funds are holding shares in HK:2269
Wuxi Biologics (Cayman) Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.67 (-0.52% Downside)
$25.67 (-0.52% Downside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
117.06%
12-Months-Change
Fundamentals
Return on Equity
8.17%
Trailing 12-Months
Asset Growth
-2.15%
Trailing 12-Months
Company Description
Wuxi Biologics (Cayman) Inc.
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
2269 Company Deck
2269 Earnings Call
Q4 2025
0:00 / 0:00
2269 Stock 12 Month Forecast
Average Price Target
HK$25.67
▼(-0.52%Downside)
Technical Analysis
Sino Biopharmaceutical
―
Innovent Biologics
―
3SBio
―
Akeso, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―